Related Experiment Video
Updated: May 25, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort
Louise Watson1, Valentina Leone, Clarissa Pilkington
1University of Liverpool and Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK.
Insights
Juvenile-onset systemic lupus erythematosus (JSLE) in the UK is characterized by severe organ involvement and high disease activity. This national cohort study highlights significant clinical manifestations and disease progression in affected children.
Area of Science:
- Rheumatology
- Pediatric Autoimmunity
- Clinical Epidemiology
Background:
- Juvenile-onset systemic lupus erythematosus (JSLE) requires better understanding of its clinical spectrum and disease course.
- The UK Juvenile-Onset Systemic Lupus Erythematosus (JSLE) Cohort Study was established to address this knowledge gap.
Purpose of the Study:
- To describe the clinical manifestations and disease course of patients with JSLE.
- To analyze data from a large, national inception cohort of children with JSLE.
Main Methods:
- A multicenter collaborative network collected detailed clinical data from 232 patients over 4.5 years.
- Patients were identified using the American College of Rheumatology (ACR) SLE classification criteria.
- The cohort included 198 children meeting ≥4 ACR criteria for SLE.
Main Results:
- The female:male sex ratio was 5.6:1, with a median age at diagnosis of 12.6 years.
- Non-Caucasian UK patients showed a greater risk of JSLE.
- High frequencies of musculoskeletal (82%), renal (80%), hematologic (91%), immunologic (54%), and neurologic (26%) involvement were observed, with 93% on steroids and 28% experiencing disease damage.
Conclusions:
- JSLE is characterized by severe organ involvement and significant disease activity in children.
- Accumulation of disease-associated damage is a notable feature in pediatric patients with JSLE.
Objective:
The UK Juvenile-Onset Systemic Lupus Erythematosus (JSLE) Cohort Study is a multicenter collaborative network established with the aim of improving the understanding of juvenile SLE. The present study was undertaken to describe the clinical manifestations and disease course in patients with juvenile SLE from this large, national inception cohort.
Methods:
Detailed data on clinical phenotype were collected at baseline and at regular clinic reviews and annual followup assessments in 232 patients from 14 centers across the UK over 4.5 years. Patients with SLE were identified according to the American College of Rheumatology (ACR) SLE classification criteria. The present cohort comprised children with juvenile SLE (n=198) whose diagnosis fulfilled ≥4 of the ACR criteria for SLE.
Results:
Among patients with juvenile SLE, the female:male sex distribution was 5.6:1 and the median age at diagnosis was 12.6 years (interquartile range 10.4-14.5 years). Male patients were younger than female patients (P<0.01). Standardized ethnicity data demonstrated a greater risk of juvenile SLE in non-Caucasian UK patients (P<0.05). Scores on the pediatric adaptation of the 2004 British Isles Lupus Assessment Group disease activity index demonstrated significantly increased frequencies of musculoskeletal (82%), renal (80%), hematologic (91%), immunologic (54%), and neurologic (26%) involvement among the patients over time. A large proportion of the patients (93%) were taking steroids and 24% of the patients required treatment with cyclophosphamide. Disease damage was common, with 28% of the patients having a Systemic Lupus International Collaborating Clinics/ACR damage score of ≥1.
Conclusion:
The data on these patients from the UK JSLE Cohort Study, comprising one of the largest national inception cohorts of patients with juvenile SLE to date, indicate that severe organ involvement and significant disease activity are primary characteristics in children with juvenile SLE. In addition, accumulation of disease-associated damage could be seen.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations
Rheumatic Heart Disease I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome I : Introduction
